Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sodium Zirconium Cyclosilicate in CKD with Hyperkalemia
NCT05056727Phase 3Terminated
- Sponsor
- AstraZeneca
- Start
- Sep 2021
- Primary completion
- Feb 2024
- Modality
- DNA Intercalators/Alkylators
- Countries
- 21
01
Overview
A Phase 3 trial of sodium zirconium cyclosilicate in hyperkalemia, sponsored by AstraZeneca. Started Sep 2021; status: terminated.
02
Drugs
sodium zirconium cyclosilicate
03
Conditions
hyperkalemia
Beyond the preview
Go deeper on NCT05056727.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05056727.